<DOC>
	<DOCNO>NCT02040246</DOCNO>
	<brief_summary>The prevalence diabetes 11.6 % accord data release 2013 China Noncommunicable Disease Surveillance Group.Less 40 % diagnosed-diabetes well controlled.Among kind antidiabetic medication , metformin recommend first-line antihyperglycemic management type 2 diabetes . Insulin secretagogue , repaglinide still one widely use antidiabetic medication China . However , study compare effect two medication glycaemic control Chinese patient type 2 diabetes .</brief_summary>
	<brief_title>Comparison Metformin Repaglinide Monotherapy Treatment New Onset Type 2 Diabetes Mellitus China</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>All participant type 2 diabetes , diagnose World Health Organization criterion , recruit outpatient Endocrinology Department Shanghai Renji Hospital Patients history coronary heart disease , abnormal renal function , active liver disease , chronic metabolic acidosis ( include diabetic ketoacidosis ) , severe chronic gastrointestinal disease .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>